An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly as it relates to using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. Today, she's Chief Business Officer at ProFluent Bio, a company that's committed to democratizing access to open-source AI gene editing tools that are custom-built for pharmaceutical development. On this episode of the Business of Biotech, Dr. Eaton shares her story and makes a pragmatic case for the transformative value of AI to biotech builders. Whether your bullish or bearish about the intersction of advanced therapeutic development and artificial intelligence, this one's a must-listen.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Bab

1. An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D. (00:00:00)

2. Exploring Career Transition in Biotech (00:00:04)

3. Navigating Rare Genetic Disease Diagnosis (00:11:06)

4. Navigating Career Shifts in Biotech (00:23:03)

5. Revolutionizing Protein Engineering With AI (00:34:24)

6. Harnessing AI and Data in Biotech (00:42:48)

7. AI Integration in Biotech Industry (00:57:18)

8. Disruptive Innovation and Collaboration in Biotech (01:05:33)